SHARE

Fior Markets launched a study titled “Erythropoietin Drugs Market by Drug Class (Biologics, Biosimilars), Product (Epoetin Alpha, Epoetin Beta, Others), Application, Regions”,and Global Forecast 2018-2025

The global erythropoietin drugs market is expected to grow from USD 7.73 Billion in 2017 to USD 18.67 Billion by 2025, at a CAGR of 11.65% during the forecast period from 2018-2025. Rising prevalence of anemia caused due to chronic diseases such as cancer, HIV AIDS, chronic kidney disease is driving the global demand for the erythropoietin drugs.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/386010/request-sample

Biosimilars erythropoietin drugs segment is anticipated to at a CAGR of 13.58% in 2018-2025

Drug class segment is divided into biologics and biosimilars. On account of patent protection, widespread use of biologics in the treatment of chronic kidney diseases, the biologics erythropoietin drugs segment emerged as the leader with USD 5.69 billion revenue in 2017. Biosimilars segment is anticipated to grow at an increased CAGR of 13.58% over the forecast period. Growing investments onresearch and developmentofbiosimilars, robust product pipeline andrise in collaborations between hospitals and manufactures for the adoption of erythropoietinbiosimilars are some of the factors that areexpected to drive the growth of the biosimilar segment.

Epotin alpha had a market value of 3.05 billion in 2017

Product is segmented into epoetin alpha, epoetin beta, darbepoetin alpha and others. Due to being the first US FDA approved biologic erythropoietin drug that is available for the treatment of anemia caused by the chemotherapy, HIV AIDS, chronic kidney disease and other similar diseases Epotin alpha product segment emerged as the largest with USD 3.05 billion revenue in 2017. On account of its improved efficacy and longer shelf life, the Epoetin beta segment also accounted for a significant share of global erythropoietin drugsmarket in 2017.

Cancer segment is projected to grow at a CAGR of 13.97% in 2018-2025

Application segment is categorized into cancer, hematology, renal disease, neurology and others. Factors such as increasing worldwide prevalence of chronic renal diseases as well as availability of specifically developed drugs such as Epogen led renal disease segment to emerge as a dominant application segment with USD 3.19 billion revenue in 2017. On account of widespread utilization oferythropoietin drugs for the treatment of the cancer patients undergoing chemotherapy, the cancer segment is anticipated to grow at an accelerated CAGR of 13.97% over the forecasted period.

BROWSE COMPLETE REPORT AND TABLE OF CONTENTS:https://www.fiormarkets.com/report/erythropoietin-drugs-market-by-drug-class-biologics-biosimilars-386010.html

Regional Segmentation Analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa.North America region led the global erythropoietin drugs market with USD 3.42 billion revenue in 2017. Factors such as rising incidence of chronic diseases like cancer, kidney failure, HIV AIDS as well as the presence of excellent healthcare facilities, growing investment on novel drug discovery activities led North America region to dominate the global demand for erythropoietin drugs.

Competitive Analysis:

Major players in the global erythropoietin drugsmarket areJohnson & Johnson, Celltrion, Inc.,Teva Pharmaceutical Industries Ltd., Pfizer Inc., Amgen, Inc., AstraZeneca, Sandoz GmbH, F. Hoffmann-La Roche Ltd., LG Life Sciences Ltd., Biocon Limited, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd, Merck Pharmaceuticals, InSight Biopharmaceuticals, BiotechnicaPharma Global, and among others.

Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.